New York, New York, USA, November 28, 2006 and Arnhem, The Netherlands, November 28, 2006 — Organon and Pfizer today announced that they have agreed to discontinue their collaboration in the further development of asenapine, a new drug candidate for the treatment of schizophrenia and acute mania associated with Bipolar I Disorder.
Pfizer’s decision to discontinue its participation in the asenapine development program is an outcome of a commercial analysis of the compound as a part of its overall portfolio. Pfizer will return all product rights, intellectual property and data to Organon and make orderly transitions during 2007.
Organon will continue to develop asenapine.
: Akzo Nobel held an Analysts' Conference Call about this subject on November 28, 2006 at 9.00 am CET. You can listen to the conference call via our webcast.